Home » Stocks » DMPI

DelMar Pharmaceuticals, Inc. (DMPI)

Aug 20, 2020 - Stock symbol was changed to KTRA
Stock Price: $1.34 USD 0.00 (0.00%)
Updated Aug 19, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 15.35M
Revenue (ttm) n/a
Net Income (ttm) -7.90M
Shares Out 11.45M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 19, 2020
Last Price $1.34
Previous Close $1.34
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.17 - 1.35
Day's Volume 0
52-Week Range 0.38 - 1.53

More Stats

Market Cap 15.35M
Enterprise Value 10.38M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.45M
Float 11.25M
EPS (basic) -1.42
EPS (diluted) -0.95
FCF / Share -0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 211,710
Short Ratio 0.24
Short % of Float 1.88%
Beta 1.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.02
Revenue n/a
Operating Income -8.28M
Net Income -7.90M
Free Cash Flow -7.16M
Net Cash 4.97M
Net Cash / Share 0.43
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -136.86%
ROE -316.72%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.00*
(123.88% upside)
Low
2.00
Current: $1.34
High
4.00
Target: 3.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-8.40-11.17-8.32-6.21-4.72
Net Income-8.05-11.14-8.08-8.86-4.35
Shares Outstanding2.572.091.201.090.95
Earnings Per Share-3.16-5.42-7.40-8.30-4.60
Operating Cash Flow-6.33-9.85-8.02-5.15-3.85
Free Cash Flow-6.33-9.85-8.02-5.15-3.85
Cash & Equivalents3.725.976.596.161.75
Net Cash / Debt3.725.976.596.161.75
Assets4.047.077.916.362.58
Liabilities2.071.641.331.503.40
Book Value1.975.446.584.86-0.82
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DelMar Pharmaceuticals, Inc.
Country United States
Employees 2
CEO Saiid Zarrabian

Stock Information

Ticker Symbol DMPI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DMPI

Description

DelMar Pharmaceuticals, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.